Identification of high levels of IL-6R and IL-6 in both tumor tissue and cyst fluid (100) has provided the impetus for trialing treatment of ACP with tocilizumab, a humanized monoclonal antibody against IL-6R. The gene discussed is IL6R; the disease is neoplasm.